Vulinacimab
Product Specifications
CAS Number
2250342-36-8
Target
VEGFR
Related Pathways
Tyrosine Kinase/Adaptors, Angiogenesis
Bioactivity
Vulinacimab (HLX-06), an anti-VEGFR-2 monoclonal antibody (mAb), plays a pivotal role in cancer research due to VEGFR-2's significant involvement in angiogenesis, as well as the proliferation, survival, migration, and differentiation of endothelial cells, processes critical for tumor growth where VEGFR-2 is overexpressed [1].
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
More Discoveries
Explore Other Products
Browse additional items from our catalog
LUN501 50 Cases / 50 Cores
Lung adenocarcinoma with lung tissue array (2015 WHO classification), including pathology grade, TNM and clinical stage (AJCC 7th edition), 50 cases/50 cores
Sign In for Pricing
View Details